Inmune Bio Inc Stock Price, News & Analysis

INmune Bio, Inc. (NASDAQ: INMB) announced two poster presentations at the 2021 British Society of Immunology Congress. The presentations highlighted the mechanism of action of INKmune, demonstrating its ability to generate memory-like NK cells and promote their proliferation. Notably, a patient treated with INKmune showed a significant increase in NK cell activation post-treatment. The presentations could have important implications for cancer therapy, showcasing INKmune's potential in enhancing NK cell function against tumors.

INmune Bio, Inc. (NASDAQ: INMB) announced its second Phase 2 trial of XPro for Mild Cognitive Impairment (MCI), alongside a previously disclosed trial for mild Alzheimer’s disease (AD). The trial aims to include 90 patients and assess cognition using the Early AD/MCI Alzheimer's Cognitive Composite (EMACC). As of September 30, 2021, the company reported cash equivalents of $84.5 million and a net loss of approximately $9.5 million for Q3 2021. The firm is also advancing its INKmune™ platform and plans to host a conference call on November 3, 2021.

INmune Bio, Inc. (NASDAQ: INMB) is set to present multiple findings at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting, taking place from November 9-12 in Boston. Key presentations include a late-breaking oral presentation on the Early Mild Alzheimer’s Cognitive Composite as a primary cognitive endpoint in a phase 2 trial of XPro1595. Additionally, various poster sessions will examine neuroinflammation biomarkers, imaging measures, and methodologies for effective trial planning. XPro1595 aims to decrease neuroinflammation, potentially improving outcomes in Alzheimer's patients.

INmune Bio, Inc. (NASDAQ: INMB) announced a conference call scheduled for November 3, 2021 at 4:30 PM ET to discuss its third quarter results ending September 30, 2021, and provide a corporate update. The call will offer insights into the company’s clinical-stage immunology initiatives, including its DN-TNF and Natural Killer Cell Priming platforms. Investors can participate via phone or a live audio webcast, with a replay available until November 10. The company emphasizes the forward-looking nature of its statements regarding clinical trials and potential product approvals.

INmune Bio, Inc. (NASDAQ: INMB) announced that Mark Lowdell, PhD, Chief Scientific Officer and Chief Medical Officer, will participate in an oncology panel titled Improving Strategies to Harness the Immune System at the B. Riley Fall 2021 Best Ideas in Oncology Series.

The panel is scheduled for September 30, 2021, at 9:00am ET and is open to institutional investors. Registration is available here.

INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology company, announced that its President and CEO, Raymond J. Tesi, MD, will present at two investor conferences in September 2021. The Oppenheimer Fall Healthcare Life Sciences & MedTech Summit will take place on September 22 at 1:15 PM ET, followed by the Cantor Fitzgerald Global Healthcare Conference on September 29 at 3:20 PM ET. Investors can arrange virtual one-on-one meetings through Oppenheimer or Cantor Fitzgerald. INmune Bio develops treatments targeting the innate immune system for various diseases.

INmune Bio has announced significant results from its Phase 1 study for XPro™, a selective DN-TNF inhibitor aimed at treating Alzheimer's disease (AD). The treatment resulted in a 46% decrease in CSF pT217, a promising biomarker for AD, and improved MRI metrics indicate remyelination. This data demonstrates reductions in biomarkers associated with neuroinflammation and neurodegeneration. A Phase 2 trial is set to begin by the end of 2021, enrolling 200 patients. Preliminary findings will be discussed in a webinar on September 7, 2021.

INmune Bio, Inc. (NASDAQ: INMB) announced positive results from the first patient receiving INKmune™ for high-risk myelodysplastic syndrome (MDS). The therapy successfully activated natural killer (NK) cells, generating memory-like NK (mlNK) cells as predicted by in vitro studies. The patient showed no adverse symptoms of Cytokine Release Syndrome (CRS) and had a doubling of NK cell numbers by day 8. The results indicate INKmune™ can effectively convert resting NK cells into more potent cancer-fighting cells, with further trials planned for additional patients.

INmune Bio, Inc. (NASDAQ: INMB) announced that President and CEO Raymond J. Tesi will present at the Canaccord Genuity 41st Annual Growth Conference from August 10 to 12, 2021. Tesi's presentation is scheduled for August 11, 2021, at 9:00 AM ET. The conference will also allow for virtual one-on-one meetings with INmune Bio representatives. The company focuses on developing treatments to enhance the innate immune system to combat diseases, with key product platforms aimed at various conditions including COVID-19, cancer, and Alzheimer's.